Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.

Experimental hematology - 1 May 2016

Kuo Ya-Huei, Qi Jing, Cook Guerry J

Abstract excerpt

Leukemia stem cells (LSCs) are self-renewable, leukemia-initiating populations that are often resistant to traditional chemotherapy and tyrosine kinase inhibitors currently used for treatment of acute or chronic myeloid leukemia. The persistence and continued acquisition of mutations in resistant LSCs represent a major cause of refractory disease and/or relapse after remission. Understanding the mechanisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to Acute Disease
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone Deacetylases

Share to Leukemia, Myeloid

Share to Neoplastic Stem Cells

Share to Repressor Proteins

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 26923266
DOI: 10.1016/j.exphem.2016.02.007
PMCID: PMC4841712

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibition.PMID 26923266Read ↗

The p53 tumor suppressor protein regulates hematopoietic stem cell fateSemantic proximity Read ↗

Nonredundant, isoform-specific roles of HDAC1 in glioma stem cells.Semantic proximity Read ↗

AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.Semantic proximity Read ↗

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8.Semantic proximity Read ↗

FLT3 inhibition upregulates HDAC8 via FOXO to inactivate p53 and promote maintenance of FLT3-ITD+ acute myeloid leukemia.Semantic proximity Read ↗

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell populationSemantic proximity Read ↗

Exploiting an Epigenetic Resistance Mechanism to PI3 Kinase Inhibition in Leukemic Stem CellsSemantic proximity Read ↗

Aspp1 Preserves Hematopoietic Stem Cell Pool Integrity and Prevents Malignant Transformation.Semantic proximity Read ↗

TP53-agnostic lethality through combined pan-HDAC and CDK inhibition in acute myeloid leukemia.Semantic proximity Read ↗

Sirt1 ablation promotes stress-induced loss of epigenetic and genomic hematopoietic stem and progenitor cell maintenanceSemantic proximity Read ↗

Mechanisms of Selective Anticancer Action of Histone Deacetylase InhibitorsSemantic proximity Read ↗

A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.